Clinical Trial Update: A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 safety and preliminary efficacy study of CC-90011 in participants with relapsed/refractory solid tumors and Non-Hodgkin lymphoma. The trial status is te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• CC-90011

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin, Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2025-04-20